Drug delivery is the technology layer that decides how a peptide actually reaches its target. The most active threads on this site: oral peptide formulations (SNAC-based oral semaglutide, oral Wegovy, Vivtex's permeability platforms), microneedle and intranasal delivery, hydrogel and nanoparticle systems for sustained release, and AAV-based gene-therapy delivery for peptide therapeutics like MeiraGTx's AQP1 program for xerostomia.
The small-molecule oral GLP-1 wave (orforglipron / Foundayo) has reframed the conversation. Once you can deliver a non-peptide GLP-1 receptor agonist by mouth, the bioavailability ceiling on peptide orals matters less for that specific indication.
Stories here cover platform launches, validation papers, and partnership deals. See #oral-peptide, #oral-glp-1, and #nanomedicine for related threads.
Researchers at Kumamoto University in Japan reported in Molecular Pharmaceutics on October 7, 2026 a small ring-shaped peptide, called SLS, that can be built into an antibody's genetic code to help it reach the brain. Attaching one SLS peptide to each heavy chain of the breast cancer antibody trastuzumab increased its passage across lab models of the blood-brain barrier and raised its brain levels after intravenous injection in mice, while its blood levels and its ability to kill HER2-positive cancer cells stayed about the same. The tag also raised brain delivery of the Alzheimer's antibody aducanumab; the work so far is in cells and mice.
Innsbruck-based Cyprumed announced on Tuesday, September 29, 2026 that MSD (Merck & Co.) has begun a Phase 1 trial of one of its proprietary drug candidates formulated with Cyprumed's oral delivery technology, the first time the technology has been tested in people; the candidate was not disclosed. Cyprumed's tablet formulations are designed to let therapeutic peptides, including GLP-1 analogs, macrocycles, and mini-proteins, be absorbed when swallowed, using approved excipients. The trial start triggers a milestone payment under the companies' April 2025 non-exclusive license and option agreement to develop oral versions of MSD's peptides, under which Cyprumed can receive up to $493 million.
Swedish drug-delivery company Nanexa announced on the evening of Thursday, September 24, 2026 a global exclusive license and collaboration agreement giving Novo Nordisk rights to use its PharmaShell platform in up to five development programs for peptide-based drugs in obesity, type 2 diabetes, and other cardiometabolic diseases. PharmaShell uses atomic layer deposition to apply an ultra-thin inorganic coating to individual drug particles to control their release, and the companies are targeting monthly and quarterly injection schedules. Nanexa can receive up to €1.165 billion, of which €615 million is an upfront payment plus development and regulatory milestones and the rest is sales milestones, along with low single-digit royalties; Novo will lead development and commercialization. Reuters reported that Nanexa's shares were up about 122% in Stockholm early on Friday, September 25.
On July 7, Vivani Medical announced a non-exclusive agreement letting Novo Nordisk evaluate NPM-139, a miniature ultra-long-acting semaglutide implant built on Vivani's NanoPortal technology and designed for once- or twice-yearly dosing. The deal grants no exclusivity over NPM-139 or the NanoPortal platform. It follows a June 25 Australian ethics-committee clearance for SLIM-1, a Phase 1 trial of NPM-139 that builds on Vivani's earlier NPM-119 exenatide implant.
Anodyne Nanotech closed a $12.6 million Series A, led by Velocity Partners, to advance ANN-101, a once-weekly GLP-1 skin patch, into first-in-human trials. The Boston company's HeroPatch solid-state microneedle platform delivers multi-milligram doses of peptides without injections or cold storage, aiming to reach the drug exposures obesity treatment requires. The round adds to a wave of investment in alternatives to weekly GLP-1 injections.
Lexaria Bioscience (NASDAQ: LEXX) announced June 9, 2026 that dosing has been completed in Animal Study #2 (GLP-1-A26-2) evaluating its DehydraTECH oral peptide delivery platform with two next-generation GLP-1 drugs: Eli Lilly's retatrutide (triple GIP/GLP-1/glucagon agonist) and Novo Nordisk's amycretin (unimolecular GLP-1/amylin agonist). The study tested formulation enhancements designed to improve DehydraTECH performance and stake intellectual property claims on next-generation oral GLP-1 delivery. The data follows Lexaria's April 23 study launch and feeds the broader oral GLP-1 platform competition with Novo Nordisk's Wegovy pill (3M US prescriptions in 5 months) and Lilly's orforglipron (Foundayo, approved April 2026). Lexaria's industry update June 17 framed the oral GLP-1 pill segment as 'billions in new industry sales' potential.
Frontiers in Pharmacology published June 18 a review on enhancing diabetes treatment through targeted nucleic acid and drug delivery using cell-penetrating peptides (CPPs), peptide nucleic acids (PNAs), and receptor targeting. The paper maps how CPPs can shuttle therapeutic cargo across cellular membranes in pancreatic-beta-cell and insulin-resistance contexts and how PNAs can modulate gene expression in diabetic targets, addressing the persistent delivery problem that limits peptide and oligonucleotide therapy. The review framing intersects with the broader push toward oral peptide delivery (Entera Bio EB613, Foundayo) and platform-driven peptide-conjugate therapeutics (Bicycle, Parabilis Medicines, MultiValent Biotherapeutics) reshaping the obesity, diabetes, and oncology spaces in 2026.
A review published May 19 in Drug Delivery and Translational Research analyzed nano-antimicrobial peptides (nano-AMPs) — antimicrobial peptides packaged into nanoparticle delivery systems — as a strategy to overcome the three barriers that have kept AMPs out of the clinic despite decades of promise: systemic toxicity, proteolytic instability, and manufacturing cost. The review focuses on activity against multidrug-resistant Gram-negative bacteria, the hardest antimicrobial-resistance target where the conventional-antibiotic pipeline is thinnest. Nanoparticle encapsulation can shield AMPs from protease degradation, reduce off-target toxicity by controlling release, and improve tissue targeting. The piece joins the broader 2026 AMP research wave — AI-designed peptides (ProteoGPT, CAMPER), generative-AI discovery in Nature Microbiology, and ancient-microbiome AMP mining — that is collectively maturing the antimicrobial peptide field toward clinical viability against the ESKAPE pathogens responsible for most drug-resistant infections.
A Nature Communications paper details crystalline mesoporous frameworks built from amphiphilic collagen-mimetic peptides (aCMPs) — charge-segregated collagen-mimetic sequences modified with lipid tails at their N-termini. Hydrophobic and electrostatic interactions drive 3D porous architectures whose lattice packing tracks with lipid-tail length (C12, C10, C8); shortening to C6 flips assembly into nanosheets. The work expands peptide-based biomaterials beyond the triple helix and offers a programmable scaffold platform for drug delivery and tissue engineering.
A WIRES Nanomedicine and Nanobiotechnology 2026 review by Garland and colleagues synthesizes the materials-science side of peptide-based cancer vaccine development: lipid nanoparticle delivery, dendrimer scaffolds, peptide self-assembly platforms, and adjuvant chemistry. The piece complements the broader review wave by focusing on delivery and formulation rather than antigen selection. Key themes: lipid-nanoparticle-encapsulated peptides show improved bioavailability and immune-cell uptake versus free peptides; self-assembling peptide hydrogels enable sustained antigen release at injection site; CpG and TLR agonist combinations remain the dominant adjuvant approach but with new variants emerging. The review positions peptide vaccines as catching up to mRNA cancer vaccines (BioNTech, Moderna programs) on delivery sophistication.
Sarfaraz K. Niazi at the University of Illinois Chicago College of Pharmacy published a March 20, 2026 review in Frontiers in Drug Delivery arguing oral peptide delivery success depends fundamentally on molecular pharmacology rather than formulation technology. The thesis: semaglutide's approval represents a rare boundary case enabled by its ~168-hour half-life and time-integrated pharmacodynamics, not a generalizable breakthrough. The author proposes a negative-selection framework identifying which peptides should be excluded from oral development — short elimination half-lives, dose sensitivity, regulatory variability constraints — and routes excluded candidates toward pulmonary, nasal, or long-acting injectable alternatives. The framework matters for the next-generation pipeline beyond Foundayo and Wegovy pill: many programs currently chasing oral delivery may be better served by alternative routes.
A team at Kumamoto University led by Associate Professor Shingo Ito developed a cyclic peptide (D-DNP-V) that ferries insulin across the small intestine. Combined with zinc-stabilized insulin hexamers and given orally to diabetes models, the platform rapidly normalized blood sugar with once-daily dosing for three consecutive days. A click-chemistry-conjugated DNP-insulin molecule performed equivalently, substantially reducing the high doses that have historically plagued oral insulin.
The Drug Discovery Chemistry Oral & Macrocyclic Peptides Summit (April 14-15, San Diego) convenes as 66 cyclic peptide drugs have gained global approval and the field races to solve oral bioavailability. Key advances include Chugai's Luna18 achieving 21-47% oral bioavailability and Merck's macrocyclic PCSK9 inhibitor enlicitide delivering injectable-level results in pill form.
A comprehensive review in Frontiers in Drug Delivery examines the barriers to oral peptide bioavailability — enzymatic degradation, poor membrane permeability, and first-pass metabolism — and maps emerging solutions including permeation enhancers, nanoparticle encapsulation, mucoadhesive systems, and microRNA-based approaches that are advancing toward clinical translation.
Several peptide-loaded hydrogels are already in Phase 3 clinical trials for chronic and acute wound care, signaling an accelerating transition from bench to pharmacy shelf.
Researchers engineered PLGA nanocomplexes functionalized with iRGD tumor-penetrating peptides to deliver paclitaxel combined with medicinal fungus extract, targeting the PDCD4 gene to overcome drug resistance.